Does the antibody production ability affect the serum anti-Helicobacter pylori IgG titer?

Table 1 Baseline characteristics of the included subjects n (%)

Variables	Subjects (n = 111)
Age (years old, mean ± SD)	55.3 ± 9.7
Gender (male:female)	66:45
Serum anti-H. pylori IgG titer (AU/mL, mean ± SD)	3.26 ± 0.97
Serum PG I level (ng/mL, mean ± SD)	72.0 ± 28.8
Serum PG II level (ng/mL, mean ± SD)	22.0 ± 9.2
Serum PG ratio (mean ± SD)	3.5 ± 1.2
Presence of corpus gastric atrophy as reflected by serum PG assay	23 (20.7)
Degree of H. pylori infiltration on biopsy
Mild	14 (12.6)
Moderate	23 (20.7)
Marked	74 (66.7)
Scores based on Updated Sydney system
Activity (mean ± SD)	1.92 ± 0.69
Chronic inflammation (mean ± SD)	2.04 ± 0.38
Atrophy (median with ranges)	0.97 (0-3)
Intestinal metaplasia (median with ranges)	0.64 (0-3)
Biopsied site
Antrum	69 (62.2)
Body or angle	36 (32.4)
Fundus or cardia	6 (5.4)
Serum HBsAb titer (mIU/mL, median with ranges)	102.19 (1-1000)
Positive HBsAb assay	78 (70.3)
Platelet (× 103/μL, mean ± SD)	235.3 ± 48.2
White blood cell count (× 103/μL, mean ± SD)	5853.8 ± 1595.9
Neutrophil (%)	56.0 ± 9.3
Lymphocyte (%)	36.4 ± 8.7
Monocyte (%)	4.7 ± 1.6
Eosinophil (%)	1.84 (0-13)
Basophil (%)	0.41 (0-5)

HBsAb: Hepatitis B surface antibody; PG: Pepsinogen; H. pylori: Helicobacter pylori.